Vivian Jiang
8PUBLICATIONS
23CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Jul 23, 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.Wei Wang, Qingsong Cai, Yang Liu
|Jul 21, 2025
YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma.Vivian Jiang, Yu Xue, Hong Kim
|Oct 07, 2024
Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.Shaojun Zhang, Vivian Changying Jiang, Guangchun Han
|May 31, 2023
Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma.Yuxuan Che, Yang Liu, Yijing Li
|Mar 30, 2022
Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.Haige Ye, Shengjian Huang, Yang Liu
|May 18, 2021
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.Shaojun Zhang, Vivian Changying Jiang, Guangchun Han
Pageof 2
Frequent Collaborators
6 joint publications
Michael Wang
3 joint publications
Chi Young Ok
2 joint publications
Shaojun Zhang
2 joint publications
Guangchun Han
2 joint publications
Rongjia Zhang
2 joint publications
Yuanxin Wang
2 joint publications
Jia Zhou
2 joint publications
Jianhua Zhang
2 joint publications
Holly Hill
2 joint publications
Andrew Futreal
